Summary
PRA Health Sciences Late Phase Services is participating in a global real world safety study program, mandated by various regulatory bodies, to confirm risk/benefit profile for a novel oral anticoagulant to assess the drug’s bleeding risk. Our ability to provide global operational oversight and efficiencies, ensure consistent communication with sites, and keep our patients engaged resulted in PRA becoming the client’s CRO of choice.
Register to download
Challenging Study Timeline Goals Achieved in Global Post-Authorization Safety Study (PASS)
You may also be interested in:
Blog
Bridging Recruitment Gaps with Academic Collaboration
Read Story
Case Study
Meeting Enrollment Goals Breast Cancer
An open-label, randomized, multi-center study to evaluate the use of Study Drug in the prevention of cancer treatment-related bone loss in…
View Resource
Webcast
THE INSIGHT SERIES: Is there any way to expedite the start-up processes for global non-interventional research? - Part 5
When new drugs are approved, the marketing authorization holders often have to commit themselves to perform additional post-authorization studies.…
View Resource
View all related content and resources for Real world solutions
Explore Insights